Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in minimal residual disease (MRD) testing and precision oncology. The acquisition builds on the companies' partnership established in 2023 and adds Personalis' NeXT Personal cancer monitoring test to Tempus' AI-driven healthcare platform. Tempus has also maintained lobbying activity around healthcare AI, reporting $60,000 in federal lobbying expenditures in each of the last five quarters focused on healthcare AI policy.
- Personalis shareholders will receive $16.25 per share, representing roughly a 6% premium to the prior closing price.
- The acquisition is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.
- Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, up 33% sequentially.
- The companies said the combined platform will strengthen cancer recurrence monitoring, biomarker discovery and personalized treatment selection.
Relevant Companies
- Tempus AI ($TEM) – Expands its oncology diagnostics portfolio and AI-enabled precision medicine platform.
- Personalis ($PSNL) – Will be acquired by Tempus under the proposed transaction.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
